MICROBOT MEDICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.865 USD | -2.81% |
|
-14.36% | -47.26% |
| Apr. 16 | HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating | MT |
| Mar. 27 | Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 12.82M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 22 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.13% | ||
| 1 week | -13.84% | ||
| Current month | -29.25% | ||
| 1 month | -20.17% | ||
| 3 months | -35.06% | ||
| 6 months | -35.54% | ||
| Current year | -46.94% |
1 week
0.86
1.10
1 month
0.861.35
Current year
0.861.63
1 year
0.864.37
3 years
0.869.60
5 years
0.8620.15
10 years
0.86192.03
| Managers | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CEO | Chief Executive Officer | 52 | 88-08-01 |
Rachel Vaknin
DFI | Director of Finance/CFO | 45 | 21-12-31 |
| Chief Tech/Sci/R&D Officer | - | Nov. 30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Burell
BRD | Director/Board Member | 59 | 16-11-27 |
| Director/Board Member | 66 | 17-12-11 | |
Tal Wenderow
BRD | Director/Board Member | 50 | 20-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.89 | -1.11% | 211,787 |
| 24-04-17 | 0.9 | -5.14% | 237,867 |
| 24-04-16 | 0.9488 | -7.88% | 254,445 |
| 24-04-15 | 1.03 | +1.98% | 179,780 |
| 24-04-12 | 1.01 | -6.48% | 128,648 |
Delayed Quote Nasdaq, April 19, 2024 at 11:55 am EDT
More quotes
Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the bodyâs vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.89
USD
Average target price
7
USD
Spread / Average Target
+686.52%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.94% | 12.82M | |
| -1.74% | 41.35B | |
| +42.15% | 40.38B | |
| +3.23% | 39.05B | |
| -12.11% | 26.67B | |
| +1.85% | 24.07B | |
| -23.67% | 18.36B | |
| -3.75% | 11.68B | |
| +21.52% | 11.6B | |
| +7.62% | 11.15B |
- Stock Market
- Equities
- MBOT Stock
